Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

SH2 domain inhibition: a problem solved?

W C Shakespeare¹

¹ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, 02139-4234, Cambridge, MA, USA

Current Opinion in Chemical Biology

|July 27, 2001

Summary

Recent advances in SH2 inhibitors have yielded promising results. Novel Src inhibitors show antiresorptive activity, while Grb2 inhibitors demonstrate potential as anticancer agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Signal transduction drug discovery: targets, mechanisms and structure-based design.

Current opinion in drug discovery & development·2009

Same author

Protein phosphorylation and signal transduction modulation: chemistry perspectives for small-molecule drug discovery.

Medicinal chemistry (Shariqah (United Arab Emirates))·2006

Same author

Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases.

British journal of cancer·2006

Same author

A novel phosphotyrosine mimetic 4'-carboxymethyloxy-3'-phosphonophenylalanine (Cpp): exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domain.

Bioorganic & medicinal chemistry letters·2001

Same author

X-Ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor.

Journal of medicinal chemistry·2001

Same author

Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption.

Bone·2001

Area of Science:

Medicinal Chemistry
Molecular Biology
Drug Discovery

Background:

Src and Grb2 are key signaling proteins involved in various cellular processes.
SH2 domains are critical for protein-protein interactions mediated by phosphotyrosine.
Inhibitors targeting SH2 domains offer therapeutic potential for diseases like cancer and bone disorders.

Purpose of the Study:

To review recent advancements in the design of Src and Grb2 SH2 inhibitors.
To highlight novel non-peptide templates and phosphotyrosine bioisosteres.
To assess the in vivo and cellular activities of newly developed inhibitors.

Main Methods:

Design and synthesis of novel non-peptide Src SH2 inhibitors.
Development of Grb2 SH2 inhibitors with modified phosphotyrosine replacements.
In vivo testing of Src inhibitors for antiresorptive activity.
In vitro cellular assays to evaluate Grb2 inhibitor efficacy as anticancer agents.

Main Results:

Several high-affinity non-peptide Src SH2 inhibitors have been developed.
One Src inhibitor, utilizing a bone-binding phosphotyrosine bioisostere, demonstrated in vivo antiresorptive activity.
Novel high-affinity Grb2 SH2 inhibitors with unique phosphotyrosine replacements have been reported.
These Grb2 inhibitors exhibited cellular activities indicative of anticancer potential.

Conclusions:

Significant progress has been made in designing effective SH2 inhibitors for Src and Grb2.
Src SH2 inhibitors show promise for treating bone-related conditions.
Grb2 SH2 inhibitors represent a potential new class of anticancer therapeutics.

Related Experiment Videos